Millennium reports 4.89M shares (4.3%) in Perspective Therapeutics
Perspective Therapeutics, Inc. Schedule 13G shows Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander reported shared voting and dispositive power over 4,893,883 shares of Common Stock, representing 4.3% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Perspective Therapeutics, Inc. Schedule 13G shows Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander reported shared voting and dispositive power over 4,893,883 shares of Common Stock, representing 4.3% of the class. The filing states they acquired beneficial ownership above 5% on 06/23/2026 but ceased to be beneficial owners above 5% by the filing date.
The cover pages list shared voting power and shared dispositive power of 4,893,883 shares. A Joint Filing Agreement dated June 29, 2026 is attached and the signatures show the filing was signed on 06/29/2026.
Key Figures
Key Terms
beneficially owned regulatory
Joint Filing Agreement regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Millennium report about Perspective Therapeutics (CATX)?
Does the Schedule 13G indicate Millennium still owns more than 5% of CATX?
Who signed the Schedule 13G for Millennium and Israel Englander?
What is the CUSIP and class of security reported in this 13G?
AI-generated analysis. How Rhea-AI works. Not financial advice.